bla bla bla

SEE you at RM2.5

wow 22x PE. good luck

apa cerita hari ni?

TOP 3.95

FPI zero debt and net cash RM215m or RM0.85/share, pay 20 cents per year also can sustain dividend for 4 years if close shop today :)

no dividend policy but the payout keep increasing. maybe coming one is 20c??

buy now or forever hold your peace! at least not making losses like ATA..

rm5 will enter klci <3

CFTC is a venture capital firm incorporated by China’s largest pure play semiconductor foundry, Semiconductor Manufacturing International Corporation (SMIC)

good results but auditor Deloitte resigned!!!

retailers were the biggest net seller of TG last friday! waliauuu

chilla big boss

Supermax june quarter RM400m
Harta june quarter RM220m
Kossan june quarter RM131m
Supermax > Harta + Kossan in profits

Supermax market cap RM26b
Harta market cap RM57b
Kossan market cap RM19b
Supermax is 1/3 of Harta + Kossan in market cap

https://www.cnbc.com/2020/08/11/russia-claims-to-have-registered-first-coronavirus-vaccine.html?__source=iosappshare%7Cnet.whatsapp.WhatsApp.ShareExtension

buy all the way down!!!!!

looks like everyone is ready to sell tomorrow!! because it will be too late to sell after the next results...;)

finally....!!!!

https://www.lazada.com.my/catalog/?q=nitrile+gloves&_keyori=ss&from=input&spm=a2o4k.searchlist.search.go.222a32ebmYDHNl

possible if gov needs more $$$, shareholders zzzzz

maybe windfall tax is coming?! similar to CPO

windfall tax coming?! same like when cpo price shot up

close eye chase? hehehehehehe

https://www.bloomberg.com/news/articles/2020-06-14/sinovac-s-vaccine-t...


Sinovac Biotech Ltd. said its coronavirus shot is safe and capable of eliciting an immune response from human trials, suggesting the shot’s potential in defending against infection of the novel coronavirus.

The Beijing-based company’s vaccine, called CoronaVac, hasn’t caused severe side effects and more than 90% of people administered with the shot on a 14-day interval have induced neutralizing antibodies two weeks after inoculation, Sinovac said in a press release on Sunday.

The preliminary findings come from phase I and II trials in China. A total of 743 healthy people ages 18 to 59 either received shots on two schedules or a placebo. More data will be uncovered from another group in the trial that received shots on a 28-day interval. Sinovac plans to publish its results in academic journals, according to a company spokesman.

Using a killed version of the coronavirus, Sinovac’s vaccine is among five Chinese experimental shots that have reached the crucial final stage of human testing before they can be approved for public use. The company announced a partnership this month with Instituto Butantan to conduct its phase III trial in Brazil, where the novel pathogen has caused the second-largest outbreak in a global pandemic that so far infected more than 7.7 million people and killed over 428,000.

Since lockdowns and social-distancing measures have helped to keep infection rates low in many countries, some of the world’s leading vaccine efforts are seeking to conduct phase III trial in active outbreaks to evaluate the effectiveness of their shots.

Authorities in Brazil have approved the vaccine co-developed by the University of Oxford and AstraZeneca Plc to carry out late stage trials there, while Cambridge, Massachusetts-based Moderna Inc. is set to go into phase III trials in the U.S.

https://www.bloomberg.com/news/articles/2020-06-14/sinovac-s-vaccine-trial-data-suggest-potential-in-virus-defense


Sinovac Biotech Ltd. said its coronavirus shot is safe and capable of eliciting an immune response from human trials, suggesting the shot’s potential in defending against infection of the novel coronavirus.

The Beijing-based company’s vaccine, called CoronaVac, hasn’t caused severe side effects and more than 90% of people administered with the shot on a 14-day interval have induced neutralizing antibodies two weeks after inoculation, Sinovac said in a press release on Sunday.

The preliminary findings come from phase I and II trials in China. A total of 743 healthy people ages 18 to 59 either received shots on two schedules or a placebo. More data will be uncovered from another group in the trial that received shots on a 28-day interval. Sinovac plans to publish its results in academic journals, according to a company spokesman.

Using a killed version of the coronavirus, Sinovac’s vaccine is among five Chinese experimental shots that have reached the crucial final stage of human testing before they can be approved for public use. The company announced a partnership this month with Instituto Butantan to conduct its phase III trial in Brazil, where the novel pathogen has caused the second-largest outbreak in a global pandemic that so far infected more than 7.7 million people and killed over 428,000.

Since lockdowns and social-distancing measures have helped to keep infection rates low in many countries, some of the world’s leading vaccine efforts are seeking to conduct phase III trial in active outbreaks to evaluate the effectiveness of their shots.

Authorities in Brazil have approved the vaccine co-developed by the University of Oxford and AstraZeneca Plc to carry out late stage trials there, while Cambridge, Massachusetts-based Moderna Inc. is set to go into phase III trials in the U.S.

please be careful, otb and kyy are switching to supermax. maybe they know comfort profit potong stim like careplus

https://www.pelhambluefund.com/2020/06/still-like-gloves-then-go-for-big-4.html

once topglove plus harta cross 10% of KLCI, $$$ will pour into this sector. supermax will enter klci too and fly like a superman

http://malaysiafinance.blogspot.com/?m=1

http://malaysiafinance.blogspot.com/?m=1

UG is obm just like supermax, benefit the most during this pandemic

https://ec.ltn.com.tw/article/breakingnews/3183126
price fell so much

yea Topglove was way back in 2013, old history and they will surely be aware and have learnt their lesson

https://www.accessdata.fda.gov/cms_ia/importalert_229.html

is this fake news?

regardless, theres also only one broker started to cover ekovest quite late, but look at the return

yes i also agree with the point that Airasia will benefit very much from weak Dollar

sell and wait for the next entry...

Brussels attack happened mid of today, not after market closed

its coming!

the closest human race ever get to curing Alzheimer

yes USD loans i saw

Triple bottom! needless to say much..

haha good one michael...

Monday sure fly! there was a huge one-off gain last year stated in the QR while this year those are real earnings

wow thanks Jay-J!

why for this company the borrowings are so high? for property development? is the earnings from property development sustainable?

thanks jay_j i am newbie. but looks like crude oil price no longer drag MYR in recent months

EG can go?

what 0.8% ? i dont get it

is the contact lens business a long shot?